Show simple item record

Article

dc.creatorSmart, Sophie E.es
dc.creatorAgbedjro, Deborahes
dc.creatorPardiñas, Antonio F.es
dc.creatorAjnakina, Olesyaes
dc.creatorAlameda, Luises
dc.creatorAndreassen, Ole A.es
dc.creatorCrespo Facorro, Benedictoes
dc.creatorMacCabe, James H.es
dc.date.accessioned2023-06-12T14:04:04Z
dc.date.available2023-06-12T14:04:04Z
dc.date.issued2022-10-12
dc.identifier.citationSmart, S.E., Agbedjro, D., Pardiñas, A.F., Ajnakina, O., Alameda, L., Andreassen, O.A.,...,MacCabe, J.H. (2022). Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium. Schizophrenia Research, 250, 1-9. https://doi.org/10.1016/j.schres.2022.09.009.
dc.identifier.issn0920-9964es
dc.identifier.urihttps://hdl.handle.net/11441/147089
dc.description.abstractIntroduction Our aim was to, firstly, identify characteristics at first-episode of psychosis that are associated with later antipsychotic treatment resistance (TR) and, secondly, to develop a parsimonious prediction model for TR. Methods We combined data from ten prospective, first-episode psychosis cohorts from across Europe and categorised patients as TR or non-treatment resistant (NTR) after a mean follow up of 4.18 years (s.d. = 3.20) for secondary data analysis. We identified a list of potential predictors from clinical and demographic data recorded at first-episode. These potential predictors were entered in two models: a multivariable logistic regression to identify which were independently associated with TR and a penalised logistic regression, which performed variable selection, to produce a parsimonious prediction model. This model was internally validated using a 5-fold, 50-repeat cross-validation optimism-correction. Results Our sample consisted of N = 2216 participants of which 385 (17 %) developed TR. Younger age of psychosis onset and fewer years in education were independently associated with increased odds of developing TR. The prediction model selected 7 out of 17 variables that, when combined, could quantify the risk of being TR better than chance. These included age of onset, years in education, gender, BMI, relationship status, alcohol use, and positive symptoms. The optimism-corrected area under the curve was 0.59 (accuracy = 64 %, sensitivity = 48 %, and specificity = 76 %). Implications Our findings show that treatment resistance can be predicted, at first-episode of psychosis. Pending a model update and external validation, we demonstrate the potential value of prediction models for TR.es
dc.formatapplication/pdfes
dc.format.extent9 p.es
dc.language.isoenges
dc.publisherElsevieres
dc.relation.ispartofSchizophrenia Research, 250, 1-9.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectTreatment resistant schizophreniaes
dc.subjectFirst episode psychosises
dc.subjectProspective longitudinal cohortes
dc.subjectPrediction modellinges
dc.subjectStratificationes
dc.subjectMachine learninges
dc.titleClinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortiumes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Psiquiatríaes
dc.relation.projectIDHEALTH-F2-2010-241909es
dc.relation.projectIDHEALTH-F2-2009-241909es
dc.relation.projectIDHEALTH-F2-2010-241909es
dc.relation.projectIDSAF2016-76046-Res
dc.relation.projectIDSAF2013-46292-Res
dc.relation.projectIDFIS 00/3095es
dc.relation.projectIDPI020499es
dc.relation.projectIDPI050427es
dc.relation.projectIDPI060507es
dc.relation.projectIDMR/L011794/1es
dc.relation.projectIDSAF2016-76046-Res
dc.relation.projectIDSAF2013-46292-Res
dc.relation.projectIDNU20-04-00393es
dc.relation.projectID51AU40_125759es
dc.relation.projectID2005-Orden sco/3246/2004es
dc.relation.projectID223273/F50es
dc.relation.projectID300309es
dc.relation.projectID283798es
dc.relation.projectIDCI 2005-0308007es
dc.relation.projectID2006233es
dc.relation.projectID2006258es
dc.relation.projectID2011085es
dc.relation.projectID2014102es
dc.relation.projectID2015088es
dc.relation.projectID2017-112es
dc.relation.projectID320030_135736/1es
dc.relation.projectID320030120686es
dc.relation.projectID324730-144064es
dc.relation.projectID320030-173211es
dc.relation.projectID171804es
dc.relation.projectIDG0500817es
dc.relation.projectID042025es
dc.relation.projectID052247es
dc.relation.projectID064607es
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0920996422003425?via%3Dihubes
dc.identifier.doi10.1016/j.schres.2022.09.009es
dc.journaltitleSchizophrenia Researches
dc.publication.volumen250es
dc.publication.initialPage1es
dc.publication.endPage9es
dc.contributor.funderCollaboration for Leadership in Applied Health Research and Care (CLAHRC) South London at King's College Hospital National Health Service Foundation Trustes
dc.contributor.funderEuropean Community (EC)es
dc.contributor.funderEuropean Community's Seventh Framework Programes
dc.contributor.funderEuropean Commission (EC). Fondo Europeo de Desarrollo Regional (FEDER)es
dc.contributor.funderFundación Marqués de Valdecillaes
dc.contributor.funderInstitute of Psychiatry, Psychology, and Neuroscience at King's College London; Psychiatry Research Trustes
dc.contributor.funderFondation Alamayaes
dc.contributor.funderInstituto de Salud Carlos IIIes
dc.contributor.funderKing's College Londones
dc.contributor.funderMaudsley Charity Research Fund.es
dc.contributor.funderMedical Research Counciles
dc.contributor.funderMinisterio de Economia, Industria y Competitividad (MINECO). Españaes
dc.contributor.funderMinistry of Health of the Czech Republices
dc.contributor.funderNational Center of Competence in Research (NCCR) "SYNAPSY - The Synaptic Bases of Mental Diseases" from the Swiss National Science Foundationes
dc.contributor.funderNational Institute for Health Research Biomedical Research Centre at South London and Maudsley National Health Service Foundation Trustes
dc.contributor.funderPlan Nacional de Drogas. Beca de investigaciónes
dc.contributor.funderResearch and Development Office of Northern Irelandes
dc.contributor.funderResearch Council of Norwayes
dc.contributor.funderSENY Fundatio Research Grantes
dc.contributor.funderSouth-Eastern Norway Regional Health Authorityes
dc.contributor.funderSwiss National Science Foundation (SNFS)es
dc.contributor.funderUK Medical Research Counciles
dc.contributor.funderUK National Institute of Health Research (NIHR) Specialist Biomedical Research Centre for Mental Health, South London and Maudsley NHS Mental Health Foundation Trust (SLaM)es
dc.contributor.funderWellcome Trustes

FilesSizeFormatViewDescription
Clinical predictors of antipsy ...622.9KbIcon   [PDF] View/Open  

This item appears in the following collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as: Atribución 4.0 Internacional